CSIMarket Company Name, Ticker, Industry, else..


Haemonetics Corporation  (NYSE: HAE)
Other Ticker:  
 

Haemonetics Corporation

HAE's Fundamental analysis



Haemonetics's sales fell by -3.74 % in the fourth quarter of 2025 from the same quarter a year ago. Ranking at No. 2166

Medical Equipment & Supplies industry recorded deterioration of revenues by -0.37 %

Haemonetics's net income grew by 184.68 % in fourth quarter of 2025 year on year, above company average,

• More on HAE's Growth


Haemonetics
current PE on trailing twelve month basis is above Medical Equipment & Supplies industry average.

Haemonetics PEG ratio is at 0.47 Company is currently trading with Price to Cash flow multiple of 27.74 in trailing twelve-month period.
Company
21.11
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.61.
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.06.


• More on HAE's Valuation
 
 Total Debt (Millions $) 1,225
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 323,107
 Net Income/Employee (TTM) $ 39,838
 Receivable Turnover (TTM) 6.56
 Tangible Book Value (Per Share $) -4.72

Haemonetics
current PE on trailing twelve month basis is above Medical Equipment & Supplies industry average.

Haemonetics PEG ratio is at 0.47 Company is currently trading with Price to Cash flow multiple of 27.74 in trailing twelve-month period.
Company
21.11
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.61.
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.06.

Haemonetics Price to Book Ratio is at 4.32 higher than Industry Avg. of -499.24, and higher than S&P 500 Avg. of 0.01

• More on HAE's Valuation

•  Market Capitalization (Millions $) 3,549
•  Shares Outstanding (Millions) 51
•  Employees 4,209
•  Revenues (TTM) (Millions $) 1,360
•  Net Income (TTM) (Millions $) 168
•  Cash Flow (TTM) (Millions $) 128
•  Capital Exp. (TTM) (Millions $) -39
•  Total Debt (Millions $) 1,225
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 323,107
•  Net Income/Employee(TTM) $ 39,838
•  Receivable Turnover Ratio (TTM) 6.56
•  Tangible Book Value (Per Share $) -4.72

•  Market Capitalization (Millions $) 3,549
•  Shares Outstanding (Millions) 51
•  Employees 4,209
•  Revenues (TTM) (Millions $) 1,360
•  Net Income (TTM) (Millions $) 168
•  Cash Flow (TTM) (Millions $) 128
•  Capital Exp. (TTM) (Millions $) -39


    HAE's Profitability Comparisons
Haemonetics achieved increase in profitability, due to cost control. Operating Margin grew in fourth quarter of 2025 to 21.55 % from 16.98 % in III. Quarter.

Haemonetics net profit margin of 17.51 % is currently ranking no. 14 in Medical Equipment & Supplies industry, ranking no. 63 in Healthcare sector and number 773 in S&P 500.


Profitability by Segment
Plasma 52.34 %
Blood Center 38.11 %
Hospital 43.06 %
Total 10.79 %



  Ratio
•   Capital Ratio (MRQ) 1.62
•  Total Debt to Equity (MRQ) 1.49
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.54
•  Inventory Turnover Ratio (TTM) 1.65



Haemonetics achieved increase in profitability, due to cost control. Operating Margin grew in fourth quarter of 2025 to 21.55 % from 16.98 % in III. Quarter.

Haemonetics net profit margin of 17.51 % is currently ranking no. 14 in Medical Equipment & Supplies industry, ranking no. 63 in Healthcare sector and number 773 in S&P 500.

• More on HAE's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com